Leqvio Pharmacokinetics (ADME): How Inclisiran Is Absorbed, Distributed, Metabolized, and Cleared

Mechanism of Action: PCSK9 Gene Silencing in Hepatocytes

Inclisiran does not neutralize circulating PCSK9 protein the way monoclonal antibodies do. It silences the gene that produces PCSK9 inside the liver cell itself, stopping the problem at its source.

After subcutaneous injection, inclisiran's GalNAc ligand binds the asialoglycoprotein receptor (ASGPR) on hepatocyte surfaces with high affinity [1]. ASGPR is expressed almost exclusively on hepatocytes at a density of approximately 500,000 receptors per cell, which explains the drug's pronounced liver tropism [2]. Once internalized through clathrin-mediated endocytosis, the siRNA escapes the endosome and loads into the RNA-induced silencing complex (RISC). The antisense strand of inclisiran then guides RISC to complementary PCSK9 messenger RNA, triggering catalytic cleavage by the Argonaute-2 enzyme [3]. A single RISC-loaded strand can destroy multiple PCSK9 mRNA transcripts. This catalytic recycling is the reason a short plasma half-life (roughly 9 hours) translates into 6 months of sustained LDL-C lowering [4]. In the ORION-10 trial (N=1,561), inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 compared with 1.0% for placebo, confirming the durability of this intracellular mechanism [5].

Absorption: Rapid Uptake from the Subcutaneous Depot

Inclisiran reaches measurable plasma concentrations quickly after a 284 mg subcutaneous dose. Peak plasma concentration (Cmax) occurs at a median of 4 hours post-injection.

Bioavailability data from the FDA clinical pharmacology review indicate that subcutaneous bioavailability is approximately 82% relative to intravenous dosing [6]. The injection site (abdomen, upper arm, or thigh) does not produce clinically meaningful differences in exposure, though abdominal injection showed slightly higher Cmax in phase I studies [7]. Plasma concentrations decline rapidly after the initial peak because inclisiran is designed to leave the bloodstream and enter liver cells, not to circulate as an active plasma drug. By 24 to 48 hours post-dose, plasma levels fall below the lower limit of quantification in most patients [6]. This fast clearance from plasma reflects efficient hepatic extraction rather than drug elimination. The pharmacologically active species is the RISC-bound antisense strand inside hepatocytes, which persists for months despite undetectable plasma drug levels. Body weight does not require dose adjustment. Population pharmacokinetic modeling across the ORION clinical program (body weight range 40 to 180 kg) showed no clinically relevant effect of weight on inclisiran exposure or LDL-C reduction [8].

Distribution: GalNAc Directs the Drug to the Liver

The distribution profile of inclisiran is defined almost entirely by its GalNAc conjugate. This is not a drug that distributes broadly into peripheral tissues.

Preclinical biodistribution studies using radiolabeled inclisiran in rodents and non-human primates demonstrated that more than 80% of the administered dose localizes to the liver within hours of subcutaneous injection [2]. Kidney tissue showed the next highest concentration, though at levels roughly 10-fold lower than liver. Minimal drug was detected in heart, lung, spleen, or skeletal muscle [6]. The volume of distribution is approximately 500 L, a value consistent with extensive tissue uptake rather than plasma retention [7]. Protein binding in plasma is moderate, ranging from 87% at lower concentrations to 75% at higher concentrations, and is concentration-dependent [6]. This pattern is typical of oligonucleotide therapeutics and does not affect clinical dosing because the drug's activity depends on intracellular delivery, not free plasma fraction.

Dr. Kausik Ray, professor of public health at Imperial College London and principal investigator of ORION-11, has noted: "The GalNAc delivery platform is what makes twice-yearly dosing possible. The drug gets into hepatocytes efficiently, loads into RISC, and stays active intracellularly long after it has disappeared from the blood" [9]. ORION-11 (N=1,617) confirmed that this distribution strategy produced time-averaged LDL-C reductions of 50.5% over 540 days [5].

Metabolism: Nucleases Replace Cytochrome P450

Inclisiran is a synthetic double-stranded RNA molecule, not a small-molecule drug. Its metabolic fate follows a completely different pathway than conventional oral medications.

The drug does not interact with cytochrome P450 enzymes. It is not a substrate, inhibitor, or inducer of any CYP isoform (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) [6]. The FDA prescribing information explicitly states that "inclisiran is not expected to cause pharmacokinetic drug interactions and clinical drug-drug interaction studies were not warranted" [10]. Metabolism occurs through nuclease-mediated degradation. Inside the hepatocyte, exonucleases and endonucleases progressively cleave the oligonucleotide backbone into shorter inactive fragments. The 2'-O-methyl and 2'-fluoro chemical modifications on inclisiran's ribose sugars slow this degradation substantially compared with unmodified RNA, which would be destroyed within minutes [3]. These modifications explain why the RISC-loaded antisense strand can persist in hepatocytes for an estimated 300 to 500 days based on preclinical kinetic modeling [2].

The metabolic end products are short oligonucleotide fragments of variable length (fewer than 12 nucleotides) that have no pharmacological activity against PCSK9 mRNA [6]. No active metabolites have been identified. This nuclease-driven metabolism is capacity-limited at supratherapeutic doses in animal studies, but at the clinical 284 mg dose in humans, no saturation of degradation pathways has been observed [7].

Excretion: Renal Clearance of Inactive Fragments

The kidneys are the primary route of elimination for inclisiran's inactive metabolites. Intact inclisiran is not meaningfully excreted in urine.

Approximately 16% of the administered dose is recovered in urine as parent drug and metabolite fragments, with the majority being degraded oligonucleotide species [6]. Renal clearance of the intact molecule is minimal because efficient hepatic uptake removes most of the drug from circulation before it can reach the glomerulus. The terminal plasma half-life is approximately 9 hours, but this value is pharmacokinetically misleading in isolation. The Endocrine Society's 2020 commentary on RNA-based lipid therapies emphasized this distinction: "For siRNA therapeutics, the plasma half-life is essentially a distribution half-life reflecting hepatocyte uptake, not a measure of drug activity duration" [11]. The pharmacodynamic half-life, defined by the duration of PCSK9 suppression, extends well beyond 6 months in most patients.

Fecal elimination accounts for a negligible fraction of the dose [6]. No biliary excretion of intact inclisiran has been identified in preclinical studies. The clinical implication is straightforward: renal impairment does not meaningfully alter drug exposure or efficacy.

Pharmacokinetics in Special Populations

Dose adjustments are not required for renal impairment, mild hepatic impairment, age, sex, race, or body weight. The clinical evidence supporting these conclusions is specific and worth examining.

Renal impairment. A dedicated renal impairment study evaluated inclisiran PK across four groups: normal renal function (eGFR ≥90), mild impairment (eGFR 60 to 89), moderate impairment (eGFR 30 to 59), and severe impairment (eGFR 15 to 29, not on dialysis) [12]. AUC increased by approximately 2.3-fold in severe renal impairment compared with normal function, but this increase did not translate into differences in LDL-C lowering or adverse events [10]. The FDA concluded that no dose adjustment is necessary for any degree of renal impairment. Patients on hemodialysis were excluded, and data remain insufficient to recommend dosing in that population.

Hepatic impairment. Patients with mild hepatic impairment (Child-Pugh A) showed comparable PK parameters to those with normal hepatic function [6]. No formal studies have been completed in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. Because ASGPR expression decreases in advanced liver disease, there is a theoretical basis for reduced hepatocyte uptake, though this has not been clinically confirmed [2].

Age and sex. Population PK analysis across the ORION program included patients aged 18 to 88 years. Neither age nor sex produced clinically significant differences in inclisiran exposure [8]. LDL-C reductions were consistent across demographic subgroups in both ORION-10 and ORION-11 [5].

Drug-Drug Interaction Profile

Inclisiran has no identified clinically significant drug-drug interactions. This is a direct consequence of its metabolic pathway.

Because the drug bypasses CYP450 entirely and does not interact with major drug transporters (P-glycoprotein, OATP1B1, OATP1B3, OAT1, OAT3, BCRP), the risk of conventional pharmacokinetic interactions is negligible [6]. Statins, ezetimibe, and other lipid-lowering therapies do not affect inclisiran's PK, and inclisiran does not alter the PK of these drugs [10]. In the ORION-10 and ORION-11 trials, 89% of patients were on concomitant statin therapy with no signal of interaction [5]. The drug is also not metabolized by or bound to P-glycoprotein, eliminating another common source of drug interactions in cardiovascular medicine [6].

One theoretical concern involves concomitant use with other PCSK9-targeting therapies (evolocumab, alirocumab). Combining a PCSK9 monoclonal antibody with inclisiran has not been studied in controlled trials. The FDA labeling does not recommend combination use, as the clinical benefit of dual PCSK9 inhibition is unproven and could produce LDL-C levels below the threshold where safety data exist [10].

Clinical PK-PD Correlation: Why Twice-Yearly Dosing Works

The disconnect between inclisiran's short plasma half-life and its prolonged pharmacodynamic effect is the most distinctive feature of its PK profile. Understanding this relationship is essential for clinicians managing dosing schedules.

After the 284 mg subcutaneous dose, PCSK9 protein levels in plasma begin to decline within 1 to 2 weeks [7]. Maximum PCSK9 suppression (approximately 80% reduction from baseline) occurs around day 30 to 60 and is maintained through day 180 [4]. LDL-C reduction follows a parallel but slightly delayed trajectory, reaching a nadir of approximately 50 to 55% reduction by day 60 to 90 and remaining below 50% reduction through day 180 in most patients [5]. The approved dosing schedule (day 1, day 90, then every 6 months) was designed around this PK-PD relationship. The day-90 dose reinforces RISC loading in hepatocytes during the period when the first dose's activity is beginning to wane. After the second dose, steady-state intracellular drug levels are achieved, and the 6-month interval maintains consistent PCSK9 suppression [8].

ORION-3, the open-label extension study, has now provided data through 4 years of twice-yearly dosing. LDL-C reductions remained stable at approximately 44 to 48% with no attenuation of effect and no evidence of anti-drug antibody formation that affected efficacy [13]. These long-term data validate the original PK modeling that predicted sustained RISC activity over years of repeat dosing.

Patients who miss a dose by up to 3 months can resume the regular schedule without restarting the loading sequence, according to the prescribing information [10]. If more than 3 months have elapsed since the missed dose, treatment restarts with day-1 and day-90 loading doses.